News zum Sektor Gesundheit aus Hong Kong (China)

 

Citi published a research report noting that bipartisan US lawmakers proposed a bill on June 2 to include US outbound investment in Chinas biotechnology sector under the review requirements of the Comprehensive Outbound Investment National Security Act (COINS Act). The proposed legislation, titled the National Security Biotechno......

CSPC PHARMA (01093.HK) announced that its subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., presented Phase I clinical data of SYS6043 in an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.The study is a multicenter, open-label, single-arm Phase I/II clinical trial (ChiCTR2400094683......

CSPC PHARMA (01093.HK) announced that its first mRNA-LNP-based dual-target chimeric antigen receptor T-cell injection (SYS6063 injection) developed by the group has been approved by the National Medical Products Administration of China to conduct clinical trials in China.The approved clinical indication is relapsed and refractor......

SIMCERE PHARMA (02096.HK) announced that the Group entered into an exclusive promotion service agreement with PrimeGenX Therapeutics in relation to Pumecitinib Gel. Pursuant to the Agreement, the Group will obtain the exclusive promotion rights for Pumecitinib Gel for all dermatology indications in Mainland China, Hong Kong, and......

FORM 8.3 PUBLIC DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION   (a) Full name of Invesco Ltd. discloser: (b) Owner or   controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and...

BELTSVILLE, Md., June 01, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere Zaiming) an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced the presentation of positive Phase 1 dose escalation data for SIM0505 at the American Society for Clinical Oncology (ASCO 2026) in Chicago, IL (poster #246). SIM0505 is an investigational antibody drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor (TOPOi) payload. NextCure plans to host a virtual KOL Event on Tuesday, June 2, 2026 (register here) to review these data....

There was HKD2.7 billion, HKD1 billion and HKD800.9 million Southbound Trading net inflow to AKESO (09926.HK), TENCENT (00700.HK) and POP MART (09992.HK).There was HKD547.5 million, HKD208.3 million and HKD200.4 million Southbound Trading net outflow from LENOVO GROUP (00992.HK), KB LAMINATES (01888.HK) and HUA HONG SEMI (01347.......

CSPC PHARMA (01093.HK) announced that it has received an upfront payment of USD1.2 billion from AstraZeneca on 29 May 2026 (after trading hours), which will bring a positive contribution to the Group's financial position. CSPC PHARMA opened 2.4% higher today and once shot up 5% to a peak of HKD7.88. It last stood at HKD7.53,......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

CSPC PHARMA (01093.HK) announced that it received an upfront payment of USD1.2 billion from AstraZeneca on May 29, 2026 (after trading hours). The receipt of the upfront payment will have a positive contribution to the Groups financial position.The Group previously entered into a strategic research and development collaboration ......

HKEX (00388.HK) announced the results of the semi-annual review of the HKEX Tech 100 Index, adding DEEPEXI TECH (01384.HK), TIME INTERCON (01729.HK), HESAI-W (02525.HK), GEEKPLUS-W (02590.HK), TRANSTHERA-B (02617.HK), CAOCAO INC (02643.HK) and YOFC (06869.HK).Stocks removed from the index include CHINA RUYI (00136.HK), TRAVELSKY......

CSPC PHARMA (01093.HK) announced that Anbenitamab Injection (brand name: Ennituo), co-developed by Shanghai JMT-BIO Technology Co., Ltd., a subsidiary of the Company, and Jiangsu Alphamab Biopharmaceuticals Co., Ltd., has received marketing authorisation from the National Medical Products Administration of the People’s Rep......

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that it will present at the Jefferies Global Healthcare Conference taking place in New York City. Ivor Elrifi, Chief Executive Officer and Keeren Shah, Chief Operating and Financial Officer of Tiziana Life Sciences, will deliver a corporate presentation highlighting the Company's recent clinical and corporate updates....

UBS published a report stating that CSPC PHARMA (01093.HK) recorded revenue of RMB6.5 billion in 1Q26, down 7.8% YoY, exceeding both the banks and market expectations. Net profit fell 41.8% YoY to RMB860 million, below the banks and market forecasts. Excluding the impact of licensing fee income, net profit declined 7.3% YoY to R......

CLSA said in a report that although CSPC PHARMA (01093.HK) shares plunged after announcing its 1Q26 results yesterday (27th), the broker believes the results were better than market concerns, with signs of recovery emerging in its core businesses. The groups 1Q26 revenue fell 7.8% YoY to RMB6.5 billion, while net profit declined......

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

UNI MEDICAL (02666.HK) announced that its wholly owned subsidiary, Genertec Universal International Leasing, has completed the issuance of the first tranche of RMB300 million notes in China today (27th).The first tranche of notes will mature in two years from today, carrying a fixed interest rate of 1.82%. (jl/da)~AASTOCKS Finan......

CSPC PHARMA (01093.HK) closed at HKD7.26 at midday, down 2.42%. After announcing at noon that its 1Q26 profit declined by 40% YoY, the stock extended losses in the afternoon and last posted at HKD6.86, down 7.8%, with turnover of 64.4347 million shares, involving HKD462 million.~AASTOCKS Financial NewsWebsite: www.aastocks.com...

CSPC PHARMA (01093.HK) announced its results for 1Q26 ended March. Revenue amounted to RMB6.465 billion, down 7.8% YoY. Net profit was RMB860 million, down 41.8% YoY; EPS was RMB0.0754.During the period, excluding fair value changes of financial assets at fair value through profit or loss and share-based employee compensation ex......

Hong Kong-listed biotech firm Insilico Medicine Cayman TopCo is considering a secondary listing in Abu Dhabi, people familiar with the matter said, in a deal that would make it the first company from outside the Gulf to list shares on a regional exchange....